Has over 40 years’ experience in the pharmaceutical industry. Led the pharmaceutical development of major tablet products and new manufacturing and formulation technologies at Wellcome (including Zovirax), set up and audited pharmaceutical plants around the world as well as conducting acquisition due diligence. He has also advised over 900 pharmaceutical/biotech companies on how to develop products to meet their clinical and commercial goals. On the commercial and business development front, as Chief Executive, built R5 Pharmaceuticals Limited into a profitable business, leading to its acquisition by Aesica Pharmaceuticals Limited after 4 years of trading. Subsequently, Paul introduced Aesica to Consort Medical plc which resulted in Aesica’s acquisition by Consort Medical for £230 million in 2014.